{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T17:29:40Z","timestamp":1725730180442},"publisher-location":"Totowa, NJ","reference-count":157,"publisher":"Humana Press","isbn-type":[{"type":"print","value":"9781617371431"},{"type":"electronic","value":"9781592598175"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004]]},"DOI":"10.1007\/978-1-59259-817-5_5","type":"book-chapter","created":{"date-parts":[[2013,6,8]],"date-time":"2013-06-08T04:19:45Z","timestamp":1370665185000},"page":"69-91","source":"Crossref","is-referenced-by-count":1,"title":["Cytokines in Multiple Myeloma"],"prefix":"10.1007","author":[{"given":"John","family":"De Vos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S0952-7915(97)80145-8","volume":"9","author":"YJ Liu","year":"1997","unstructured":"Liu YJ, de Bouteiller O, Fugier-Vivier I. Mechanisms of selection and differentiation in germinal centers. Curr Opin Immunol 1997; 9:256\u2013262.","journal-title":"Curr Opin Immunol"},{"key":"5_CR2","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.4049\/jimmunol.159.8.3757","volume":"159","author":"J Choe","year":"1997","unstructured":"Choe J, Kim HS, Armitage RJ, Choi YS. The functional role of B cell antigen receptor stimulation and IL-4 in the generation of human memory B cells from germinal center B cells. J Immunol 1997; 159:3757\u20133766.","journal-title":"J Immunol"},{"key":"5_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1074-7613(00)80578-6","volume":"8","author":"TD Randall","year":"1998","unstructured":"Randall TD, Heath AW, Santos-Argumedo L, Howard MC, Weissman IL, Lund FE. Arrest of B lymphocyte terminal differentiation by CD40 signaling: mechanism for lack of antibody-secreting cells in germinal centers. Immunity 1998; 8:733\u2013742.","journal-title":"Immunity"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1126\/science.7537388","volume":"268","author":"C Arpin","year":"1995","unstructured":"Arpin C, Dechanet J, Van Kooten C, et al. Generation of memory B cells and plasma cells in vitro. Science 1995; 268:720\u2013722.","journal-title":"Science"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<508::AID-IMMU508>3.0.CO;2-I","volume":"28","author":"J Choe","year":"1998","unstructured":"Choe J, Choi YS. IL-10 interrupts memory B cell expansion in the germinal center by inducing differentiation into plasma cells. Eur J Immunol 1998; 28:508\u2013515.","journal-title":"Eur J Immunol"},{"key":"5_CR6","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.4049\/jimmunol.159.6.2652","volume":"159","author":"S Jacquot","year":"1997","unstructured":"Jacquot S, Kobata T, Iwata S, Morimoto C, Schlossman SF. CD 154\/CD40 and CD70\/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. J Immunol 1997; 159: 2652\u20132657.","journal-title":"J Immunol"},{"key":"5_CR7","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.4049\/jimmunol.130.6.2597","volume":"130","author":"DF Jelinek","year":"1983","unstructured":"Jelinek DF, Lipsky PE. The role of B cell proliferation in the generation of immunoglobulinsecreting cells in man. J Immunol 1983; 130:2597\u20132604.","journal-title":"J Immunol"},{"key":"5_CR8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.4049\/jimmunol.148.2.404","volume":"148","author":"L Vernino","year":"1992","unstructured":"Vernino L, McAnally LM, Ramberg J, Lipsky PE. Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated with anti-CD3-activated T cells. J Immunol 1992; 148:404\u2013410.","journal-title":"J Immunol"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000206293","volume":"73","author":"P Gavarotti","year":"1985","unstructured":"Gavarotti P, Boccadoro M, Redoglia V, Golzio F, Pileri A. Reactive plasmacytosis: case report and review of the literature. Acta Haematol 1985; 73:108\u2013110.","journal-title":"Acta Haematol"},{"key":"5_CR10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1182\/blood.V94.2.701","volume":"94","author":"G Jego","year":"1999","unstructured":"Jego G, Robillard N, Puthier D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999; 94:701\u2013712.","journal-title":"Blood"},{"key":"5_CR11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.V100.4.1113.h81602001113_1113_1122","volume":"100","author":"K Tarte","year":"2002","unstructured":"Tarte K, De Vos J, Thykjaer T, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002; 100:1113\u20131122.","journal-title":"Blood"},{"key":"5_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/art.1780330313","volume":"33","author":"M Jourdan","year":"1990","unstructured":"Jourdan M, Bataille R, Seguin J, Zhang XG, Chaptal PA, Klein B. Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum 1990; 33:398\u2013402.","journal-title":"Arthritis Rheum"},{"key":"5_CR13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.4049\/jimmunol.109.6.1386","volume":"109","author":"R MacMillan","year":"1972","unstructured":"MacMillan R, Longmire RL, Yelenosky R, Lang JE, Heath V, Craddock CG. Immunoglobulin synthesis by human lymphoid tissues : normal bone marrow as a major site of IgG production. J Immunol 1972; 109:1386\u20131390.","journal-title":"J Immunol"},{"key":"5_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/eji.1830160206","volume":"16","author":"T Hibi","year":"1986","unstructured":"Hibi T, Dosch HM. Limiting dilution analysis of the B cell compartment in human bone marrow. Eur J Immunol 1986; 16:139\u2013145.","journal-title":"Eur J Immunol"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/1521-4141(200204)32:4<923::AID-IMMU923>3.0.CO;2-1","volume":"32","author":"RA Manz","year":"2002","unstructured":"Manz RA, Radbruch A. Plasma cells for a lifetime? Eur J Immunol 2002; 32:923\u2013927.","journal-title":"Eur J Immunol"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1073\/pnas.86.19.7547","volume":"86","author":"S Suematsu","year":"1989","unstructured":"Suematsu S, Matsuda T, Aozasa K, et al. IgG 1 plasmacytosis in interleukin 6 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1989; 86:7547\u20137551.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1084\/jem.167.2.332","volume":"167","author":"A Muraguchi","year":"1988","unstructured":"Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2\/ IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167:332\u2013340.","journal-title":"J Exp Med"},{"key":"5_CR18","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1002\/eji.1830211105","volume":"21","author":"E Roldan","year":"1991","unstructured":"Roldan E, Brieva JA. Terminal differentiation of human bone marrow cells capable of spontaneous and high-rate immunoglobulin secretion: role of bone marrow stromal cells and interleukin 6. Eur J Immunol 1991; 21:2671\u20131677.","journal-title":"Eur J Immunol"},{"key":"5_CR19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood.V85.2.487.487","volume":"85","author":"MM Kawano","year":"1995","unstructured":"Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995; 85:487\u2013494.","journal-title":"Blood"},{"key":"5_CR20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/eji.1830240214","volume":"24","author":"JA Brieva","year":"1994","unstructured":"Brieva JA, Roldan E, Rodriguez C, Navas G. Human tonsil, blood and bone marrow in vivoinduced B cells capable of spontaneous and high-rate immunoglobulin secretion in vitro: differences in the requirements for factors and for adherent and bone marrow stromal cells, as well as distinctive adhesion molecule expression. Eur J Immunol 1994; 24:362\u2013366.","journal-title":"Eur J Immunol"},{"key":"5_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1084\/jem.183.1.227","volume":"183","author":"P Merville","year":"1996","unstructured":"Merville P, Dechanet J, Desmouliere A, et al. Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J Exp Med 1996; 183:227\u2013236.","journal-title":"J Exp Med"},{"key":"5_CR22","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1084\/jem.175.6.1739","volume":"175","author":"E Roldan","year":"1992","unstructured":"Roldan E, Garcia-Pardo A, Brieva JA. VLA-4-fibronectin interaction is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate immunoglobulin secretion. J Exp Med 1992; 175:1739\u20131747.","journal-title":"J Exp Med"},{"key":"5_CR23","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.4049\/jimmunol.171.4.1684","volume":"171","author":"G Cassese","year":"2003","unstructured":"Cassese G, Arce S, Hauser AE, et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003; 171:1684\u20131690.","journal-title":"J Immunol"},{"key":"5_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/40540","volume":"388","author":"RA Manz","year":"1997","unstructured":"Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 1997; 388:133\u2013134.","journal-title":"Nature"},{"key":"5_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","volume":"8","author":"MK Slifka","year":"1998","unstructured":"Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8:363\u2013372.","journal-title":"Immunity"},{"key":"5_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0952-7915(98)80162-3","volume":"10","author":"MK Slifka","year":"1998","unstructured":"Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998; 10:252\u2013258.","journal-title":"Curr Opin Immunol"},{"key":"5_CR27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/bj3340297","volume":"334","author":"PC Heinrich","year":"1998","unstructured":"Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp 130\/Jak\/STAT pathway. Biochem J 1998; 334:297\u2013314.","journal-title":"Biochem J"},{"key":"5_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/332083a0","volume":"332","author":"M Kawano","year":"1988","unstructured":"Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and essential requirement of BSF-2\/IL-6 for human multiple myeloma. Nature 1988; 332:83\u201385.","journal-title":"Nature"},{"key":"5_CR29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V73.2.517.517","volume":"73","author":"B Klein","year":"1989","unstructured":"Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myelomacell growth and differentiation by interleukin-6. Blood 1989; 73:517\u2013526.","journal-title":"Blood"},{"key":"5_CR30","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V83.12.3654.3654","volume":"83","author":"XG Zhang","year":"1994","unstructured":"Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83:3654\u20133663.","journal-title":"Blood"},{"key":"5_CR31","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.4049\/jimmunol.161.6.2692","volume":"161","author":"M Ferlin-Bezombes","year":"1998","unstructured":"Ferlin-Bezombes M, Jourdan M, Liautard J, Brochier J, Rossi JF, Klein B. IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. J Immunol 1998; 161:2692\u20132699.","journal-title":"J Immunol"},{"key":"5_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/sj.leu.2401632","volume":"14","author":"ZJ Gu","year":"2000","unstructured":"Gu ZJ, De Vos J, Rebouissou C, et al. Agonist anti-gp 130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 2000; 14:188\u2013197.","journal-title":"Leukemia"},{"key":"5_CR33","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1172\/JCI114392","volume":"84","author":"R Bataille","year":"1989","unstructured":"Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84:2008\u20132011.","journal-title":"J Clin Invest"},{"key":"5_CR34","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/blood.V77.12.2794.2794","volume":"77","author":"H Ludwig","year":"1991","unstructured":"Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991; 77:2794\u20132795.","journal-title":"Blood"},{"key":"5_CR35","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.V78.5.1198.1198","volume":"78","author":"B Klein","year":"1991","unstructured":"Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78:1198\u20131204.","journal-title":"Blood"},{"key":"5_CR36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V80.3.733.733","volume":"80","author":"R Bataille","year":"1992","unstructured":"Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80:733\u2013737.","journal-title":"Blood"},{"key":"5_CR37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863","volume":"85","author":"B Klein","year":"1995","unstructured":"Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85:863\u2013872.","journal-title":"Blood"},{"key":"5_CR38","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","volume":"82","author":"H Uchiyama","year":"1993","unstructured":"Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82:3712\u20133720.","journal-title":"Blood"},{"key":"5_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1046\/j.1365-2141.1998.00517.x","volume":"100","author":"AC Bloem","year":"1998","unstructured":"Bloem AC, Lamme T, de Smet M, et al. Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMCdependent cell lines. Br J Haematology 1998; 100:166\u2013175.","journal-title":"Br J Haematology"},{"key":"5_CR40","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1046\/j.1365-2141.1998.01101.x","volume":"103","author":"V Costes","year":"1998","unstructured":"Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 1998; 103:1152\u20131160.","journal-title":"Br J Haematol"},{"key":"5_CR41","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V86.2.685.bloodjournal862685","volume":"86","author":"R Bataille","year":"1995","unstructured":"Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86:685\u2013691.","journal-title":"Blood"},{"key":"5_CR42","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/blood.V86.8.3123.3123","volume":"86","author":"ZY Lu","year":"1995","unstructured":"Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995; 86:3123\u20133131.","journal-title":"Blood"},{"key":"5_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/0167-5699(95)80161-8","volume":"16","author":"B Klein","year":"1995","unstructured":"Klein B, Brailly H. Cytokine-binding proteins: stimulating antagonists. Immunol Today 1995; 16:216\u2013220.","journal-title":"Immunol Today"},{"key":"5_CR44","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1126\/science.3726549","volume":"233","author":"RP Nordan","year":"1986","unstructured":"Nordan RP, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986; 233:566\u2013569.","journal-title":"Science"},{"key":"5_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1432-1033.1988.tb14267.x","volume":"176","author":"RJ Simpson","year":"1988","unstructured":"Simpson RJ, Moritz RL, Rubira MR, Van Snick J. Murine hybridoma\/plasmacytoma growth factor: complete amino-acid sequence and relation to human interleukin-6. Eur J Biochem 1988; 176:187\u2013197.","journal-title":"Eur J Biochem"},{"key":"5_CR46","first-page":"689","volume":"151","author":"G Lattanzio","year":"1997","unstructured":"Lattanzio G, Libert C, Aquilina M, et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB\/c mice. Am J Pathol 1997; 151:689\u2013696.","journal-title":"Am J Pathol"},{"key":"5_CR47","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1073\/pnas.89.1.232","volume":"89","author":"S Suematsu","year":"1992","unstructured":"Suematsu S, Matsusaka T, Matsuda T, et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1992; 89:232\u2013235.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"5_CR48","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1084\/jem.182.1.243","volume":"182","author":"DM Hilbert","year":"1995","unstructured":"Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995; 182:243\u2013248.","journal-title":"J Exp Med"},{"key":"5_CR49","first-page":"1195","volume":"24","author":"ZJ Gu","year":"1996","unstructured":"Gu ZJ, Zhang XG, Hallet MM, et al. A ciliary neurotrophic factor-sensitive human myeloma cell line. Exp Hematol 1996; 24:1195\u20131200.","journal-title":"Exp Hematol"},{"key":"5_CR50","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood.V88.10.3972.bloodjournal88103972","volume":"88","author":"ZJ Gu","year":"1996","unstructured":"Gu ZJ, Costes V, Lu ZY, et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996; 88:3972\u20133986.","journal-title":"Blood"},{"key":"5_CR51","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1126\/science.276.5320.1851","volume":"276","author":"MB Rettig","year":"1997","unstructured":"Rettig MB, Ma HJ, Vescio RA, et al. Kaposi\u2019s sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997; 276:1851\u20131854.","journal-title":"Science"},{"key":"5_CR52","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood.V91.6.1858","volume":"91","author":"R Burger","year":"1998","unstructured":"Burger R, Neipel F, Fleckenstein B, et al. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 1998; 91:1858\u20131863.","journal-title":"Blood"},{"key":"5_CR53","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1182\/blood.V91.6.1852","volume":"91","author":"K Tarte","year":"1998","unstructured":"Tarte K, Olsen SJ, Lu ZY, et al. Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi\u2019s sarcoma-associated herpesvirus. Blood 1998; 91:1852\u20131857.","journal-title":"Blood"},{"key":"5_CR54","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1182\/blood.V93.10.3159.410a40b_3159_3163","volume":"93","author":"K Tarte","year":"1999","unstructured":"Tarte K, Chang Y, Klein B. Kaposi\u2019s sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. Blood 1999; 93:3159\u20133163.","journal-title":"Blood"},{"key":"5_CR55","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood.V85.9.2521.bloodjournal8592521","volume":"85","author":"ZY Lu","year":"1995","unstructured":"Lu ZY, Zhang XG, Rodriguez C, et al. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995; 85:2521\u20132527.","journal-title":"Blood"},{"key":"5_CR56","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/0014-5793(95)01322-9","volume":"377","author":"ZY Lu","year":"1995","unstructured":"Lu ZY, Gu ZJ, Zhang XG, et al. Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines. FEBS Lett 1995; 377:515\u2013518.","journal-title":"FEBS Lett"},{"key":"5_CR57","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood.V75.6.1305.1305","volume":"75","author":"G Tosato","year":"1990","unstructured":"Tosato G, Jones KD. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood 1990; 75:1305\u20131310.","journal-title":"Blood"},{"key":"5_CR58","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","volume":"87","author":"CA Dinarello","year":"1996","unstructured":"Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095\u20132147.","journal-title":"Blood"},{"key":"5_CR59","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.V73.8.2145.2145","volume":"73","author":"M Kawano","year":"1989","unstructured":"Kawano M, Tanaka H, Ishikawa H, et al. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 1989; 73:2145\u20132148.","journal-title":"Blood"},{"key":"5_CR60","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V74.1.380.380","volume":"74","author":"F Cozzolino","year":"1989","unstructured":"Cozzolino F, Torcia M, Aldinucci D, et al. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74:380\u2013387.","journal-title":"Blood"},{"key":"5_CR61","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2141.1990.tb06330.x","volume":"74","author":"A Carter","year":"1990","unstructured":"Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br J Haematol 1990; 74:424\u2013431.","journal-title":"Br J Haematol"},{"key":"5_CR62","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.1993.tb03331.x","volume":"85","author":"M Borset","year":"1993","unstructured":"Borset M, Helseth E, Naume B, Waage A. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br. J Haematol 1993; 85:446\u2013451.","journal-title":"Br. J Haematol"},{"key":"5_CR63","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1073\/pnas.93.10.4885","volume":"93","author":"RM Hinson","year":"1996","unstructured":"Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci U S A 1996; 93:4885\u20134890.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR64","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.V73.6.1646.1646","volume":"73","author":"M Kawano","year":"1989","unstructured":"Kawano M, Yamamoto I, Iwato K, et al. Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 1989; 73:1646\u20131649.","journal-title":"Blood"},{"key":"5_CR65","first-page":"868","volume":"24","author":"M Torcia","year":"1996","unstructured":"Torcia M, Lucibello M, Vannier E, et al. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Exp Hematol 1996; 24:868\u2013874.","journal-title":"Exp Hematol"},{"key":"5_CR66","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.V95.2.610","volume":"95","author":"I Tinhofer","year":"2000","unstructured":"Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000; 95:610\u2013618.","journal-title":"Blood"},{"key":"5_CR67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1046\/j.1365-2141.1999.01510.x","volume":"106","author":"H Hjorth-Hansen","year":"1999","unstructured":"Hjorth-Hansen H, Waage A, Borset M. Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. Br J Haematol 1999; 106:28\u201334.","journal-title":"Br J Haematol"},{"key":"5_CR68","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood.V88.2.479.bloodjournal882479","volume":"88","author":"KJ Till","year":"1996","unstructured":"Till KJ, Burthem J, Lopez A, Cawley JC. Granulocyte-macrophage colony-stimulating factor receptor: stage-specific expression and function on late B cells. Blood 1996; 88:479\u2013486.","journal-title":"Blood"},{"key":"5_CR69","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1046\/j.1365-2141.1998.00880.x","volume":"102","author":"A Villunger","year":"1998","unstructured":"Villunger A, Egle A, Kos M, et al. Functional granulocyte\/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity. Br J Haematol 1998; 102:1069\u20131080.","journal-title":"Br J Haematol"},{"key":"5_CR70","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V76.12.2599.2599","volume":"76","author":"XG Zhang","year":"1990","unstructured":"Zhang XG, Bataille R, Jourdan M, et al. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990; 76:2599\u20132605.","journal-title":"Blood"},{"key":"5_CR71","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1365-2141.1993.tb03341.x","volume":"85","author":"M Portier","year":"1993","unstructured":"Portier M, Zhang XG, Ursule E, et al. Cytokine gene expression in human multiple myeloma. Br J Haematol 1993; 85:514\u2013520.","journal-title":"Br J Haematol"},{"key":"5_CR72","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/blood.V78.2.539.539","volume":"78","author":"D Nachbaur","year":"1991","unstructured":"Nachbaur D, Herold M, Huber H. Endogenous circulating granulocyte-macrophage colonystimulating factor in multiple myeloma. Blood 1991; 78:539\u2013540.","journal-title":"Blood"},{"key":"5_CR73","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1046\/j.1365-2141.1996.02298.x","volume":"94","author":"D Peest","year":"1996","unstructured":"Peest D, Blade J, Harousseau JL, Klein B, Osterborg A, San Miguel JF. Cytokine therapy in multiple myeloma. Br. J Haematol 1996; 94:425\u2013432.","journal-title":"Br. J Haematol"},{"key":"5_CR74","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1600-0609.1985.tb01568.x","volume":"35","author":"G Brenning","year":"1985","unstructured":"Brenning G. The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol 1985; 35:178\u2013185.","journal-title":"Scand J Haematol"},{"key":"5_CR75","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1365-2141.1994.tb04821.x","volume":"86","author":"A Palumbo","year":"1994","unstructured":"Palumbo A, Battaglio S, Napoli P, et al. Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells. Br J Haematol 1994; 86:726\u2013732.","journal-title":"Br J Haematol"},{"key":"5_CR76","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1172\/JCI119179","volume":"99","author":"DF Jelinek","year":"1997","unstructured":"Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ. Differential human multiple myeloma cell line responsiveness to interferon-alpha: analysis of transcription factor activation and interleukin 6 receptor expression. J Clin Invest 1997; 99:447\u2013456.","journal-title":"J Clin Invest"},{"key":"5_CR77","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.147.12.4402","volume":"147","author":"M Jourdan","year":"1991","unstructured":"Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol 1991; 147:4402\u20134407.","journal-title":"J Immunol"},{"key":"5_CR78","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.4049\/jimmunol.170.7.3717","volume":"170","author":"JD French","year":"2003","unstructured":"French JD, Walters DK, Jelinek DF. Transactivation of gp130 in myeloma cells. J Immunol 2003; 170:3717\u20133723.","journal-title":"J Immunol"},{"key":"5_CR79","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood.V89.1.261","volume":"89","author":"LC Berger","year":"1997","unstructured":"Berger LC, Hawley RG. Interferon-beta interrupts interleukin-6-dependent signaling events in myeloma cells. Blood 1997; 89:261\u2013271.","journal-title":"Blood"},{"key":"5_CR80","doi-asserted-by":"publisher","first-page":"11799","DOI":"10.1074\/jbc.273.19.11799","volume":"273","author":"T Arora","year":"1998","unstructured":"Arora T, Jelinek DF. Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression. J Biol Chem 1998; 273:11799\u201311805.","journal-title":"J Biol Chem"},{"key":"5_CR81","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/sj.leu.2401334","volume":"13","author":"P Liu","year":"1999","unstructured":"Liu P, Oken M, Van Ness B. Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis. Leukemia 1999; 13:473\u2013480.","journal-title":"Leukemia"},{"key":"5_CR82","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1002\/eji.1830261244","volume":"26","author":"A Egle","year":"1996","unstructured":"Egle A, Villunger A, Kos M, et al. Modulation of Apo-1\/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Eur J Immunol 1996; 26:3119\u20133126.","journal-title":"Eur J Immunol"},{"key":"5_CR83","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.V92.8.2914","volume":"92","author":"H Spets","year":"1998","unstructured":"Spets H, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Fas\/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood 1998; 92:2914\u20132923.","journal-title":"Blood"},{"key":"5_CR84","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1073\/pnas.91.4.1198","volume":"91","author":"JU Gutterman","year":"1994","unstructured":"Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 1994; 91:1198\u20131205.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR85","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2141.1991.tb08068.x","volume":"79","author":"J Blade","year":"1991","unstructured":"Blade J, Lopez-Guillermo A, Tassies D, Montserrat E, Rozman C. Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br J Haematol 1991; 79:523\u2013525.","journal-title":"Br J Haematol"},{"key":"5_CR86","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2141.1992.tb06484.x","volume":"82","author":"M Sawamura","year":"1992","unstructured":"Sawamura M, Murayama K, Ui G, et al. Plasma cell leukaemia with alpha-interferon therapy in myeloma. Br J Haematol 1992; 82:631.","journal-title":"Br J Haematol"},{"key":"5_CR87","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1182\/blood.V74.5.1718.1718","volume":"74","author":"H Tanaka","year":"1989","unstructured":"Tanaka H, Tanabe O, Iwato K, et al. Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells. Blood 1989; 74:1718\u20131722.","journal-title":"Blood"},{"key":"5_CR88","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood.V81.11.3076.3076","volume":"81","author":"M Portier","year":"1993","unstructured":"Portier M, Zhang XG, Caron E, Lu ZY, Bataille R, Klein B. gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 1993; 81:3076\u20133082.","journal-title":"Blood"},{"key":"5_CR89","doi-asserted-by":"publisher","first-page":"16351","DOI":"10.1074\/jbc.272.26.16351","volume":"272","author":"NK Ossina","year":"1997","unstructured":"Ossina NK, Cannas A, Powers VC, et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997; 272: 16351\u201316357.","journal-title":"J Biol Chem"},{"key":"5_CR90","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","volume":"281","author":"A Ashkenazi","year":"1998","unstructured":"Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305\u20131308.","journal-title":"Science"},{"key":"5_CR91","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.274.5288.787","volume":"274","author":"DJ Antwerp Van","year":"1996","unstructured":"Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alphainduced apoptosis by NF-kappaB. Science 1996; 274:787\u2013789.","journal-title":"Science"},{"key":"5_CR92","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S1074-7613(00)80390-8","volume":"7","author":"SY Lee","year":"1997","unstructured":"Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 1997; 7:703\u2013713.","journal-title":"Immunity"},{"key":"5_CR93","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1600-0609.1994.tb00176.x","volume":"53","author":"M Borset","year":"1994","unstructured":"Borset M, Waage A, Brekke OL, Helseth E. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol 1994; 53:31\u201337.","journal-title":"Eur J Haematol"},{"key":"5_CR94","first-page":"65","volume":"10","author":"M Jourdan","year":"1999","unstructured":"Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999; 10:65\u201370.","journal-title":"Eur Cytokine Netw"},{"key":"5_CR95","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","volume":"20","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20:4519\u20134527.","journal-title":"Oncogene"},{"key":"5_CR96","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood.V74.4.1266.1266","volume":"74","author":"A Lichtenstein","year":"1989","unstructured":"Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989; 74:1266\u20131273.","journal-title":"Blood"},{"key":"5_CR97","first-page":"52","volume":"20","author":"X Filella","year":"1996","unstructured":"Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM. Cytokines (IL-6, TNF-alpha, IL-1 alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect Prey 1996; 20:52\u201356.","journal-title":"Cancer Detect Prey"},{"key":"5_CR98","first-page":"90","volume":"351","author":"J Blade","year":"1997","unstructured":"Blade J, Filella X, Montoto S, et al. Clinical relevance of interleukin 6 and tumor necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance [abstract]. Blood 1997; 90:351a.","journal-title":"Blood"},{"key":"5_CR99","first-page":"249","volume":"55","author":"R Baserga","year":"1995","unstructured":"Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995; 55:249\u2013252.","journal-title":"Cancer Res"},{"key":"5_CR100","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/369414a0","volume":"369","author":"G Christofori","year":"1994","unstructured":"Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994; 369:414\u2013418.","journal-title":"Nature"},{"key":"5_CR101","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1126\/science.279.5350.563","volume":"279","author":"JM Chan","year":"1998","unstructured":"Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279:563\u2013566.","journal-title":"Science"},{"key":"5_CR102","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1182\/blood.V88.6.2250.bloodjournal8862250","volume":"88","author":"P Georgii-Hemming","year":"1996","unstructured":"Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996; 88:2250\u20132258.","journal-title":"Blood"},{"key":"5_CR103","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood.V88.9.3546.bloodjournal8893546","volume":"88","author":"T Nishiura","year":"1996","unstructured":"Nishiura T, Karasuno T, Yoshida H, et al. Functional role of cation-independent mannose 6-phosphate\/insulin-like growth factor II receptor in cell adhesion and proliferation of a human myeloma cell line OPM-2. Blood 1996; 88:3546\u20133554.","journal-title":"Blood"},{"key":"5_CR104","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4049\/jimmunol.159.1.487","volume":"159","author":"DF Jelinek","year":"1997","unstructured":"Jelinek DF, Witzig TE, Arendt BK. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 1997; 159:487\u2013496.","journal-title":"J Immunol"},{"key":"5_CR105","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1046\/j.1365-2141.2000.02364.x","volume":"111","author":"M Ferlin","year":"2000","unstructured":"Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an IL-6-independent transduction pathway. Br J Haematol 2000; 111:626\u2013634.","journal-title":"Br J Haematol"},{"key":"5_CR106","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood.V96.8.2856","volume":"96","author":"NL Ge","year":"2000","unstructured":"Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96:2856\u20132861.","journal-title":"Blood"},{"key":"5_CR107","first-page":"3909","volume":"60","author":"W Li","year":"2000","unstructured":"Li W, Hyun T, Heller M, et al. Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth. Cancer Res 2000; 60:3909\u20133915.","journal-title":"Cancer Res"},{"key":"5_CR108","doi-asserted-by":"crossref","first-page":"20388","DOI":"10.1016\/S0021-9258(17)32004-5","volume":"269","author":"T Arai","year":"1994","unstructured":"Arai T, Parker A, Busby W, Jr., Clemmons DR. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factorbindingprotein complexes. J Biol Chem 1994; 269:20388\u201320393.","journal-title":"J Biol Chem"},{"key":"5_CR109","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/ng0797-260","volume":"16","author":"M Chesi","year":"1997","unstructured":"Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p 16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics 1997; 16:260\u2013264.","journal-title":"Nature Genetics"},{"key":"5_CR110","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2003-04-1204","volume":"102","author":"ON Onwuazor","year":"2003","unstructured":"Onwuazor ON, Wen XY, Wang DY, et al. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 2003; 102:772\u2013773.","journal-title":"Blood"},{"key":"5_CR111","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.V92.8.2987","volume":"92","author":"NS Fracchiolla","year":"1998","unstructured":"Fracchiolla NS, Luminari S, Baldini L, Lombardi L, Maiolo AT, Neri A. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. Blood 1998; 92:2987\u20132989.","journal-title":"Blood"},{"key":"5_CR112","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1126\/science.8456318","volume":"259","author":"M Kan","year":"1993","unstructured":"Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993; 259:1918\u20131921.","journal-title":"Science"},{"key":"5_CR113","first-page":"767","volume":"81","author":"RC Ridley","year":"1993","unstructured":"Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. 1993; 81:767\u2013774.","journal-title":"Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen"},{"key":"5_CR114","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1046\/j.1365-2141.1998.00623.x","volume":"100","author":"M Jourdan","year":"1998","unstructured":"Jourdan M, Ferlin M, Legouffe E, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic mveloma cells. Br J Haematol 1998: 100:637\u2013646.","journal-title":"Br J Haematol"},{"key":"5_CR115","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/10428199809057596","volume":"31","author":"TE Witzig","year":"1998","unstructured":"Witzig TE, Kimlinger T, Stenson M, Therneau T. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1998; 31:167\u2013175.","journal-title":"Leuk Lymphoma"},{"key":"5_CR116","doi-asserted-by":"publisher","first-page":"14713","DOI":"10.1074\/jbc.272.23.14713","volume":"272","author":"SV Subramanian","year":"1997","unstructured":"Subramanian SV, Fitzgerald ML, Bernfield M. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 1997; 272:14713\u201314720.","journal-title":"J Biol Chem"},{"issue":"99","key":"5_CR117","first-page":"368","volume":"1997","author":"MV Dhodapkar","year":"1998","unstructured":"Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma [published erratum appears in Br J Haematol 1998 May;101(2):398]. Br J Haematol 1997; 99:368\u2013371.","journal-title":"May;101(2):398]. Br J Haematol"},{"key":"5_CR118","volume-title":"Activation molecules on human myeloma cells. Curr Topics Microbiol Immunol","author":"B Klein","year":"1999","unstructured":"Klein B, Li XY, Lu ZY, et al. Activation molecules on human myeloma cells. Curr Topics Microbiol Immunol 1999. In press."},{"key":"5_CR119","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1182\/blood.V100.2.610","volume":"100","author":"Y Yang","year":"2002","unstructured":"Yang Y, Yaccoby S, Liu W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002; 100:610\u2013617.","journal-title":"Blood"},{"key":"5_CR120","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nm0698-691","volume":"4","author":"M Kato","year":"1998","unstructured":"Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 1998; 4:691\u2013697.","journal-title":"Nat Med"},{"key":"5_CR121","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1182\/blood-2002-09-2907","volume":"101","author":"G Bisping","year":"2003","unstructured":"Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003; 101:2775\u20132783.","journal-title":"Blood"},{"key":"5_CR122","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood.V93.9.3064","volume":"93","author":"A Vacca","year":"1999","unstructured":"Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93:3064\u20133073.","journal-title":"Blood"},{"key":"5_CR123","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1083\/jcb.129.5.1177","volume":"129","author":"R Zarnegar","year":"1995","unstructured":"Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 1995; 129:1177\u20131180.","journal-title":"J Cell Biol"},{"key":"5_CR124","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood.V88.10.3998.bloodjournal88103998","volume":"88","author":"M Borset","year":"1996","unstructured":"Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-met in multiple mveloma. Blood 1996: 88:3998\u20134004.","journal-title":"Blood"},{"key":"5_CR125","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V91.3.806","volume":"91","author":"C Seidel","year":"1998","unstructured":"Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage AElevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998; 91:806\u2013812.","journal-title":"Blood"},{"key":"5_CR126","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.1073\/pnas.93.15.7644","volume":"93","author":"M Grano","year":"1996","unstructured":"Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A 1996; 93:7644\u20137648.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR127","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1182\/blood.V94.11.3883","volume":"94","author":"O Hjertner","year":"1999","unstructured":"Hjertner O, Torgersen ML, Seidel C, et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999; 94:3883\u20133888.","journal-title":"Blood"},{"key":"5_CR128","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood.V98.3.771","volume":"98","author":"J Vos De","year":"2001","unstructured":"De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001; 98:771\u2013780.","journal-title":"Blood"},{"key":"5_CR129","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1038\/sj.onc.1205355","volume":"21","author":"YD Wang","year":"2002","unstructured":"Wang YD, De Vos J, Jourdan M, et al. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene 2002; 21:2584\u20132592.","journal-title":"Oncogene"},{"key":"5_CR130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2741\/A241","volume":"3","author":"KM Davis-Fleischer","year":"1998","unstructured":"Davis-Fleischer KM, Besner GE. Structure and function of heparin-binding EGF-like growth factor (HB-EGF). Frontiers in Bioscience 1998; 3:d288-d299.","journal-title":"Frontiers in Bioscience"},{"key":"5_CR131","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","volume":"87","author":"A Vacca","year":"1994","unstructured":"Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J Haematol 1994; 87:503\u2013508.","journal-title":"Br. J Haematol"},{"key":"5_CR132","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","volume":"95","author":"B Dankbar","year":"2000","unstructured":"Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95:2630\u20132636.","journal-title":"Blood"},{"key":"5_CR133","first-page":"728","volume":"59","author":"WT Bellamy","year":"1999","unstructured":"Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59:728\u2013733.","journal-title":"Cancer Res"},{"key":"5_CR134","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565\u20131571.","journal-title":"N Engl J Med"},{"key":"5_CR135","doi-asserted-by":"publisher","first-page":"11581","DOI":"10.1073\/pnas.201394498","volume":"98","author":"RN Pearse","year":"2001","unstructured":"Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE\/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001; 98:11581\u201311586.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR136","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","volume":"98","author":"N Giuliani","year":"2001","unstructured":"Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98:3527\u20133533.","journal-title":"Blood"},{"key":"5_CR137","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","volume":"98","author":"PI Croucher","year":"2001","unstructured":"Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98:3534\u20133540.","journal-title":"Blood"},{"key":"5_CR138","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","volume":"100","author":"M Abe","year":"2002","unstructured":"Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)- l alpha and MIP-1 beta in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100:2195\u20132202.","journal-title":"Blood"},{"key":"5_CR139","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0952-7915(02)00407-7","volume":"14","author":"F Mackay","year":"2002","unstructured":"Mackay F, Kalled SL. TNF ligands and receptors in autoimmunity: an update. Curr Opin Immunol 2002; 14:783\u2013790.","journal-title":"Curr Opin Immunol"},{"key":"5_CR140","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood-2002-01-0008","volume":"100","author":"JO Claudio","year":"2002","unstructured":"Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002; 100:2175\u20132186.","journal-title":"Blood"},{"key":"5_CR141","first-page":"203","volume":"3","author":"K Tarte","year":"2002","unstructured":"Tarte K, Moreaux J, Legouffe E, Rossi JF, Klein B. BAFF Is a survival factor for multiple myeloma cells [abstract]. Blood 2002; Abstract 3 203.","journal-title":"Blood"},{"key":"5_CR142","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood.V88.1.82.82","volume":"88","author":"E Sitnicka","year":"1996","unstructured":"Sitnicka E, Ruscetti FW, Priestley GV, Wolf NS, Bartelmez SH. Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. Blood 1996; 88:82\u201388.","journal-title":"Blood"},{"key":"5_CR143","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.4049\/jimmunol.147.10.3342","volume":"147","author":"R Jansen","year":"1991","unstructured":"Jansen R, Damia G, Usui N, et al. Effects of recombinant transforming growth factor-beta 1 on hematologic recovery after treatment of mice with 5-fluorouracil. J Immunol 1991; 147:3342\u20133347.","journal-title":"J Immunol"},{"key":"5_CR144","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/eji.1830250230","volume":"25","author":"T Matthes","year":"1995","unstructured":"Matthes T, Werner-Favre C, Zubler RH. Cytokine expression and regulation of human plasma cells: disappearance of interleukin-10 and persistence of transforming growth factorbeta 1. Eur J Immunol 1995: 25:508\u2013512.","journal-title":"Eur J Immunol"},{"key":"5_CR145","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1073\/pnas.95.1.189","volume":"95","author":"SR Amoroso","year":"1998","unstructured":"Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ. Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas. Proc Natl Acad Sci U S A 1998; 95:189\u2013194.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR146","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.146.8.2865","volume":"146","author":"DJ Berg","year":"1991","unstructured":"Berg DJ, Lynch RG. Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor-beta contributes to the altered expression of activation receptors on host B lymphocytes. J Immunol 1991; 146:2865\u20132872.","journal-title":"J Immunol"},{"key":"5_CR147","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V87.5.1928.1928","volume":"87","author":"M Urashima","year":"1996","unstructured":"Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor-beta l : differential effects on multiple myeloma versus normal B cells. Blood 1996; 87:1928\u20131938.","journal-title":"Blood"},{"key":"5_CR148","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood.V87.8.3375.bloodjournal8783375","volume":"87","author":"T Tsujimoto","year":"1996","unstructured":"Tsujimoto T, Lisukov IA, Huang N, Mahmoud MS, Kawano MM. Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells. Blood 1996; 87: 3375\u20133383.","journal-title":"Blood"},{"key":"5_CR149","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/BF02989591","volume":"15","author":"MC Kyrtsonis","year":"1998","unstructured":"Kyrtsonis MC, Repa C, Dedoussis GV, et al. Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma. Med Oncol 1998; 15:124\u2013128.","journal-title":"Med Oncol"},{"key":"5_CR150","first-page":"760","volume":"88","author":"RM Lemoli","year":"1994","unstructured":"Lemoli RM, Fortuna A, Grande A, et al. Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells. 1994; 88:760\u2013769.","journal-title":"Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells"},{"key":"5_CR151","first-page":"613","volume":"170","author":"L Bergui","year":"1989","unstructured":"Bergui L, Schena M, Gaidano G, Riva M, Caligaris C. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. 1989; 170:613\u2013618.","journal-title":"Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma"},{"key":"5_CR152","first-page":"585","volume":"5","author":"Y Okuno","year":"1991","unstructured":"Okuno Y, Takahashi T, Suzuki A, et al. Establishment and characterization of four myeloma cell lines which are responsive to interleukin-6 for their growth. Leukemia 1991; 5:585\u2013591.","journal-title":"Leukemia"},{"key":"5_CR153","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood.V73.7.1915.1915","volume":"73","author":"KC Anderson","year":"1989","unstructured":"Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73:1915\u20131924.","journal-title":"Blood"},{"key":"5_CR154","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","volume":"91","author":"M Hallek","year":"1998","unstructured":"Hallek M, Leif BP, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91:3\u201321.","journal-title":"Blood"},{"key":"5_CR155","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/sj.leu.2400564","volume":"11","author":"I Riet van","year":"1997","unstructured":"Van Riet I, De Greef C, Aharchi F, et al. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2). Leukemia 1997; 11:284\u2013293.","journal-title":"Leukemia"},{"key":"5_CR156","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1073\/pnas.90.5.2060","volume":"90","author":"A Degrassi","year":"1993","unstructured":"Degrassi A, Hibert DM, Rudikoff S, Anderson AO, Potter M, Coon HG. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Nat Acad Sci U S A 1993; 90:2060\u20132064.","journal-title":"Proc Nat Acad Sci U S A"},{"key":"5_CR157","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1074\/jbc.M208636200","volume":"278","author":"K Podar","year":"2003","unstructured":"Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 2003; 278:5794\u20135801.","journal-title":"J Biol Chem"}],"container-title":["Biology and Management of Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-59259-817-5_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:57:44Z","timestamp":1715475464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-59259-817-5_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"ISBN":["9781617371431","9781592598175"],"references-count":157,"URL":"https:\/\/doi.org\/10.1007\/978-1-59259-817-5_5","relation":{},"subject":[],"published":{"date-parts":[[2004]]}}}